A carregar...
Prostate-Specific Antigen Velocity Risk Count Improves the Specificity of Screening for Clinically Significant Prostate Cancer
OBJECTIVE: Prostate-specific antigen (PSA)-based prostate cancer (CaP) screening has been shown to reduce CaP mortality at the expense of detecting some tumors that might never cause symptoms. PSA velocity (PSAV) has been shown to predict cancer-specific mortality after treatment. Our objective was...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3338148/ https://ncbi.nlm.nih.gov/pubmed/22296334 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1464-410X.2011.10900.x |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|